SGCB and fibrosis: Anti-fibrotic effects of drugs influencing the NO/sGC/sGMP pathway such as the sGC stimulator riociguat were demonstrated in both acute and advanced bile duct ligation model and the acute CCl4 fibrosis model whereas no significant decreases in markers like hydroxyproline were also described [42].